
TVRD Stock Forecast & Price Target
TVRD Analyst Ratings
Bulls say
Tvardi Therapeutics is poised for success due to its two potential game-changing oral, small molecule therapies targeting STAT3, a protein associated with inflammatory and proliferative diseases. Positive results from TTI-109's clinical trials, including improved tolerability and safety, coupled with TTI-101's promising preclinical and Phase 1 results, indicate the potential for strong market performance. With sufficient funding and plans for expanded collaborations and indications, Tvardi's pipeline is well-equipped for success in the competitive biopharmaceutical industry.
Bears say
Tvardi Therapeutics is a company with a promising pipeline, but their financials and recent stock performance suggest caution. With a current cash position that may not last until Phase 3 trials are completed and no products on the market yet, there are risks associated with investing in this company. Additionally, Tvardi's success is highly dependent on the success of its lead products, and any setbacks or delays could significantly impact its future prospects.
This aggregate rating is based on analysts' research of Cara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TVRD Analyst Forecast & Price Prediction
Start investing in TVRD
Order type
Buy in
Order amount
Est. shares
0 shares